StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Botox Cosmetic (onabotulinumtoxinA) by Quarter

Botox Cosmetic (onabotulinumtoxinA) — International reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Botox Cosmetic (onabotulinumtoxinA): 16.4% in Q2 2026, up 15.5 pts from a year earlier.

Latest, Q2 2026
16.4%
Period ended Jun 30, 2026
Change on a year earlier
+15.5 pts
0.9% in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Botox Cosmetic | 400 | 328 | 728 | (2.4) | 16.4 | 5.2 | 12.1 | 3.4”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBotox Cosmetic (onabotulinumtoxinA) — International reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202616.4%+15.5 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202613.9%+7.0 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202514.7%+17.2 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20250.7%-10.2 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 20250.9%-4.3 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 20256.9%+9.1 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024-2.5%-23.1 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202410.9%+24.2 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20245.2%-2.7 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-2.2%-11.6 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202320.6%+24.6 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-13.3%-54.3 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20237.9%-5.0 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20239.4%-23.1 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-4.0%-24.3 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 202241.0%+19.4 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Botox Cosmetic (onabotulinumtoxinA) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/botox-cosm-intl-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.